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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not oral
finasteride is effective in reversing hair loss in men with androgenetic alopecia.
STUDY DESIGN: Review of two double blind, randomized controlled trials (RCTs), and one
randomized open-label study published between 2009 and 2013, all in English language. The
articles compared oral finasteride to a placebo, topical finasteride, and Serenoa repens,
respectively.
DATA SOURCES: The two double-blind, randomized controlled trials (RCTs), and one
randomized open-label study were found using PubMed. All articles were published in peerreviewed journals and selected based on correlation to topic choice, date of publication, and
evaluating POEMs.
OUTCOMES MEASURED: Patient reported satisfaction with therapy, change in staging from
baseline as measured by the Hamilton and the Hamilton-Norwood Classification Scale for
androgenetic alopecia, and change in mean size of alopecia from baseline (cm).
RESULTS: The three studies used in this review demonstrated inconsistent data on the
effectiveness of oral finasteride for reversing hair loss in men with androgenetic alopecia. Rossi
et al. demonstrated a statistically significant change in hair growth reversal in men taking oral
finasteride when compared to Serenoa repens (P=0.013). Gubelin Harcha et al found statistically
significant data that men treated with oral finasteride perceived they had increase in hair growth
at the end of the trial when compared to the placebo. However, Gubelin Harcha et al found
statistically insignificant data to support that men were overall satisfied with hair growth at the
end of the trial (P=0.084). Hajheydari et al. demonstrated oral finasteride was statistically
insignificant in reversing hair loss in men when compared to topical finasteride.
KEY WORDS: finasteride, androgenetic alopecia
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INTRODUCTION
Male androgenetic alopecia, also known as male pattern balding, is the most common
cause of hair loss in men.1 Androgenetic alopecia is a condition that affects the hair follicles,
resulting in a pattern of hair thinning and hair loss. It is characterized by a progressive
transformation of terminal hair into villus hair. 1,2 The age of onset for androgenetic alopecia in
men is generally in the late teens and early twenties but varies, and prevalence has been found to
increase with age. Approximately 80% of men above the age of 60 are affected, and roughly
16% of men ages 18-29 and 53% of men ages 40-49 exhibit moderate to extensive androgenetic
alopecia. 1,3,4 The disorder is around 4 times more common in Caucasian men than in African
American men. When compared to Caucasian men, androgenetic alopecia affected men of
Chinese origin less frequently and at a later age. In men of Japanese origin, the age of onset of
androgenetic alopecia was found to be approximately 10 years after that of Caucasian men.4
Male pattern balding is believed to have both an endocrine and genetic component. The
main hormone that is linked to androgenetic alopecia is testosterone, specifically
dihydrotestosterone (DHT), and active metabolite of testosterone. 1-6 DHT is converted from
testosterone by the enzyme 5-alpha-reductse.1-6 There are two isoforms of 5-alpha-reductase that
are able to convert testosterone to DHT, Type 1 and Type 2.2,4-6 Type 1 is mostly found in the
hair follicles and the sebaceous glands of the skin, whereas Type 2 is generally found in the inner
root sheath of hair follicles and the male genitalia and prostate.4,6 Higher concentrations of 5alpha-reductase in the body are linked with androgenetic alopecia in men.2
Evidence suggests that androgenetic alopecia also has a familial component and
polygenic inheritance.1,2 Twin studies show an 80% predisposition to hair loss. Polygenic
inheritance is also supported by evidence that there is an increased risk for androgenetic alopecia

	
  

Anderson, Finasteride for Androgenetic Alopecia

2	
  

in families with increased number of affected individuals2. This is thought to be due to an
abnormality of the androgen-receptor gene on the X-chromosome, which would lead to maternal
inheritance of androgenetic alopecia, as well as a mutated locus on chromosome 3.2
Current FDA approved medications for hair restoration due to androgenetic alopecia
include topical minoxidil (Rogaine) and oral finasteride.1,2,6 Other off-label medications used to
help reverse hair loss are dutasteride, latanoprast, and topical finasteride.2,5 Hair transplant
surgery is also an effective therapeutic option for long-term treatment of androgenetic alopecia.
1,2,4

It is estimated that millions of dollars are spent annually on products to help reverse hair

loss.4

Objective
The objective of this selective EBM review is to determine whether or not oral finasteride is
effective in reversing hair loss in men with androgenetic alopecia (male pattern baldness).

Method
Two randomized control studies and one randomized open label study were used in this
review. These studies consisted of men ages 18 and older diagnosed with androgenetic alopecia.
Gubelin Harcha et al. compared the effectiveness of 4 control groups receiving either 0.02mg,
0.1 or 0.5mg/day of dutasteride or a placebo, and an experimental group receiving 1mg/day of
finasteride. Each of the 5 groups received their randomly assigned medication daily for a total of
24 weeks. At the 12th and 24th week of the experiment, a 3-question Hair Growth Index (HGI)
questionnaire was given to each participant to assess their subjective perception of their amount
of hair. The HGI included a 7-point scale that ranged from “much less hair” to “much more
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hair”. Each participant was also given a 5-question Hair Growth Satisfaction Scale (HGSS)
which was administered at 12 and 24 weeks to assess the participants’ satisfaction. The HGSS
also had a 7-point scale that ranged from “very dissatisfied” to “very satisfied”. Gubelin Harcha
et al. also used the Hamilton-Norwood Classification Scale to assess each participant’s change in
stage of androgenetic alopecia at the end of the 24-week trial. The change in each participant’s
staging was used to assess their therapeutic response. The secondary outcomes measured in this
study were hair growth, change in terminal hair count, and an investigator photographic
assessment questionnaire; however, these outcomes are not addressed in this paper.6
Hajheydari et al. conducted a double-blind randomized clinical trial to compare the
effectiveness of a control group of topical finasteride gel with an experimental group receiving 1
mg of finasteride per day by mouth. Effectiveness of treatment was evaluated by comparing
change in the size of alopecia in centimeters for both groups at the end of the 6-month trial and
the overall effectiveness of each therapy measured after each month. Secondary outcomes
measured in this study were hair count and change in number of terminal hairs at the end of the
study; however; these secondary outcomes are not considered POEMS and will not be addressed
in this paper.5
Rossi et al. conducted a randomized open label study comparing a control group of
Serenoa repens, a plant also known as saw palmetto, with the experimental group of oral
finasteride for the treatment of male androgenetic alopecia. This experiment measured the
outcomes of each therapy for 24 months. Outcomes were measured by comparing the Hamilton
Classification scores of each participant at the beginning of the trial to their score at the end of
the 24 months. The subjective therapeutic effectiveness for both therapies was also evaluated by
three dermatologists, however these outcomes are not reviewed in this paper.3
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The studies above were found using PubMed. The keywords used for PubMed were
finasteride and alopecia. Articles that evaluated outcomes that measured patient oriented
evidence that matters (POEM’s) from 2007-2017 were selected. The population studied was men
ages 18 and older that have androgenetic alopecia. Populations excluded were women, children
under the age of 18, and those with hair loss due to etiologies other than androgenetic alopecia.
The statistics reported in these articles were p-values (p<0.05 were considered clinically
significant), number needed to treat, and mean change from baseline. Table 1 shows the
demographics and characteristics of the included studies.

Outcomes Measured
The patient oriented outcomes measured in these trials were patient satisfaction with the
therapy at the end of the trial, mean change in size of alopecia, subjective overall effectiveness of
therapy at the end of the trial, and overall change in rating of alopecia based on the Hamilton
Classification Scale for androgenetic alopecia. Gubelin Harcha et al. used the HamiltonNorwood Classification Scale to evaluate change in the participants’ baseline androgenetic
alopecia to assess their response to therapy at the end of 24 weeks. They also used a 3-qusetion
survey and a 5-question survey at the 12th and 24th week to assess to the participants’ perception
of the therapeutic effectiveness of the randomly assigned medication they received. Hajheydari
et al. compared the size of the area of alopecia (cm) before and after the trial was conducted.
Rossi et al. used the Hamilton Classification Scale to compare each participants’ stage of
androgenetic alopecia from before the trial to their staging at the end of the trial. The change in
staging was used to assess the participant’s response to therapy.
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Table 1: Demographics and Characteristics of included studies
Study

Type

Gubelin1

Double
Blind RCT

Hajheydari2 Double
Blind RCT

Rossi 3

	
  

#
Age
Pts (yrs)
917 Men
20-50

45

Exclusion
Criteria
-serum
testosterone less
than 250 ng/dL
-unstable liver
disease
-h/o malignancy
within prior 5 yrs
-prostate CA in
-Maintain
1st degree
same hair
-PSA > 2.0
color & style ng/ML
-hair loss not
caused by
androgenetic
alopecia
-any
condition/disease
of scalp/hair
Men
-Males < 30 -Males with
Under with
androgenetic
30
androgenetic alopecia who are
alopecia
under treated
Hair loss less -males with
than 5 yrs
baseline disease
-max
that causes hair
diameter of
loss
hair loss less
than 10cm

Randomized 100 Men
open label
20-40
study

Inclusion
Criteria
-Alopecia
type III
vertex, IV, V
(based off
HamiltonNorwood
scale)

Mild to
moderate
androgenetic
alopecia
based on
Hamilton
classification

W/D Interventions
156

PO finasteride
1.0 mg/d x 6
months

7

PO finasteride
1.0mg/d x 6
months

-Surgical
0
alteration of scalp
-topical minoxidil
use in previous
year
-Men with
alopecia as result
of other causes

PO finasteride
1.0mg/d x 24
months
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Results
The double-blind randomized clinical trial conducted by Gubelin Harcha et al. included
917 men between the ages 20-50 years old. Of the 917 men participating, 761 completed the
trial. Twenty-one withdrew from the trial due to adverse events, 9 due to protocol deviation, 48
participants were lost to follow up, 20 were released at investigator discretion, and 58 withdrew
consent. All of the participants were diagnosed with androgenetic alopecia and were classified
as either type III vertex, IV, or V based of the Hamilton-Norwood Classification Scale.
Participants were randomly assigned to either one of the four control groups (Placebo,
dutasteride 0.02mg/day PO, dutasteride 0.1mg/day PO, dutasteride 0.5mg/day PO) or the
experimental group (finasteride 1mg/day PO). 181 participants were randomly assigned to the
placebo group, 185 participants were assigned to dutasteride 0.02mg/day PO, 188 were assigned
Dutasteride 0.1mg/day PO, 184 were assigned dutasteride 0.5mg/day PO, and 179 were assigned
finasteride 1mg/day PO. This review focused on using the placebo as the control group with
1mg oral finasteride as the experimental group.6
Using the Hamilton-Norwood Classification scale for androgenetic alopecia, participants
were classified at the end of 24 weeks as either worsening in stage, unchanged stage, or
improvement in stage. To dichotomize the data found in Table IV of Gubelin Harcha et al., this
review classified participants as either improved from baseline or unimproved from baseline at
the end of 24 weeks. This data is found in Table IV of Gubelin Harcha et. al. Table 2 shows the
control event rate (CER), experimental event rate (EER), relative benefit increase (RBI),
absolute benefit increase (ABI), and the calculated numbers needed to treat (NNT).6
Gubelin Harcha et al. also used a 3 question HGI and a 5 question HGSS to assess
participants satisfaction with the therapy they received. At week 24, participants receiving 1mg
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tablet of finasteride had a mean increase of 2.5 and participants receiving the placebo had a mean
increase of 1.1 on the HGI score (P< .001), a finding that is statistically significant. Participants
receiving finasteride had a mean increase of 10.1 on the HGSS, while participants receiving the
placebo had a mean increase in 9.1 on the HGSS (P = 0.084), which is statistically insignificant.6
Table 2. Baseline Change in Hamilton-Norwood Classification in Gubelin Harcha et. al.
CER
EER
RBI
ABI
NNT
0.185
0.267
0.443
.082
13
The double-blind randomized control study conducted by Hajheydari et al. included 45
men between the ages of 18 and 35 years old clinically diagnosed with androgenetic alopecia.
Of the 45 men, 7 participants were excluded from the trial. Participants were randomly divided
into two groups. Group A received topical finasteride gel and a placebo tablet. Group B
received a placebo gel and an oral tablet of finasteride 1mg. Participants were instructed to take
their assigned tablet once daily and apply their assigned topical gel twice daily.
Hajheydari et al. measured the size of alopecia (cm2) of participants before and after the 6-month
trial. Before the trial, the average size of alopecia in participants taking oral finasteride 1mg
daily was 7.55 cm with a standard deviation of 2.28cm. At the end of the 6-month trial, the
average size of alopecia was recorded as 7.18cm with a standard deviation of 2.17cm. The pvalue was found to be 0.07, which is statistically insignificant. Table 3 shows the mean change
from baseline in participants using oral finasteride and topical finasteride.5
Table 3: Average Change in Size of Alopecia in Hajheydari et al.
Finasteride
Finasteride gel Finasteride tablet at Finasteride gel at
Tablet Baseline baseline
24 months
24 months
Size of
7.55
7.21
7.18
6.72
alopecia (cm)
Standard
2.28
2.08
2.17
2.41
Deviation
p-value
0.07
0.08
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Rossi et al. conducted a randomized open label study with 100 men diagnosed with
androgenetic alopecia, all completing the trial. The participants were equally separated into two
groups and treated with oral finasteride 1mg/day or Serenoa repens 320 mg/day. In Table IIIa
of Ross et al. the results of the Hamilton Classification score to assess the hair growth of
participants treated with oral finasteride at the end of 24 months. Rossi et al. classified
participants as worsened, stable, or improved based of their Hamilton Classification at the end of
the 24-month trial is shown.* This review dichotomized the data by classifying the participants
as either improved or unimproved. The unimproved category includes both the worsened and
stable classifications by Rossi et. al. Of the 50 participants treated with finasteride, 34 were
categorized as improved, and 16 were categorized as worsened or stable. A chi-square of 6.09
and a p-value of 0.013 were reported for this data and show that the data is significantly
significant. Table 4 of this review shows the CER, EER, RBI, ABI, and NNT of the trial
conducted by Rossi et al.3

Table 4. Therapeutic response of oral finasteride compared to Serenoa repens by Rossi et
al.
CER
EER
RBI
ABI
NNT
0.38
0.68
0.79
.30
4
Discussion
Finasteride is a 5-alpha reductase inhibitor that was approved in 1997 by the FDA to treat
androgenetic alopecia4. The two randomized control trials and the one randomized open label
study discussed in this paper examined the therapeutic advantage of oral finasteride in reversing
hair loss in adult men diagnosed with androgenetic alopecia.
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When compared to a placebo in Gubelin Harcha et al., oral finasteride was found to have
a NNT of 13, which represents a large treatment effect. A NNT of 13 means that for every 13
patients treated with 1 mg/day of PO finasteride, one patient with androgenetic alopecia will
experience an improvement of hair growth. Participants treated with finasteride showed a
statistically significant subjective improvement in their amount of hair at the end of the 24-week
trial. The p-value for the HGSS was greater than 0.05, indicating that participants treated with
oral finasteride did not have significant improvement in satisfaction of therapy when compared
to the placebo. One limitation of this study is the use of subjective questionnaires to assess
therapeutic effectiveness of interventions, as participants may have different expectations of
outcomes of therapy. Other limitations of this study are only including men between the ages of
20 to 50 years old, and the short duration of the trial.
The study conducted by Hajheydari et al. showed finasteride did not have significant
improvement in hair growth when compared to topical finasteride gel. Limitations of this study
include the number participants, only including men under the age of 30, and excluding male
with androgenetic alopecia for over 5 years.
Rossi et al. found a significant improvement in hair growth for participants taking oral
finasteride when compared to Serenoa repens. This study found a NNT of 4, meaning that for
every 4 patients treated with finasteride, 1 will show improvement in hair growth in men with
androgenetic alopecia. Limitations of this study include using only men between the ages of 20
and 40, using an open-label study, and comparing finasteride with a plant extract that is not FDA
approved for the treatment of androgenetic alopecia in men.
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Conclusion
The two randomized control trials and one randomized open label study examined in this
review showed inconsistent data on whether or not 1mg of oral finasteride was effective in
reversing hair loss in men with androgenetic alopecia. Future studies should consider
investigating the effect finasteride has on hair loss for a longer duration, on populations younger
than 18 who have been diagnosed with androgenetic alopecia, effectiveness of different doses of
PO finasteride, and the effect PO finasteride has on women suffering from androgenetic
alopecia. This review studied the effectiveness of oral finasteride in reversing hair loss in men
with androgenetic alopecia.
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